• FTSE 100

    -15.95 (-0.22%)
  • FTSE 250

    -20.22 (-0.09%)
  • AIM

    +8.94 (+0.73%)

    +0.0022 (+0.19%)

    +0.0024 (+0.1718%)

    +693.10 (+2.97%)
  • CMC Crypto 200

    -6.76 (-0.83%)
  • S&P 500

    +3.83 (+0.09%)
  • DOW

    -20.80 (-0.06%)

    +0.74 (+1.02%)

    +9.80 (+0.55%)
  • NIKKEI 225

    -9.24 (-0.03%)

    +507.31 (+1.79%)
  • DAX

    -179.94 (-1.15%)
  • CAC 40

    -60.43 (-0.91%)

Cellular Immunotherapy Global Market Report 2021: COVID 19 Growth And Change to 2030

·4-min read

Major players in the cellular immunotherapy market are Novartis AG, Gilead Sciences Inc. (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp (GC Pharma), AstraZeneca, Bristol-Myers Squibb, Pfizer Inc.

New York, June 09, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cellular Immunotherapy Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06090633/?utm_source=GNW
, and Roche.

The global cellular immunotherapy market is expected to grow from $2.74 billion in 2020 to $3.59 billion in 2021 at a compound annual growth rate (CAGR) of 31%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $6.73 billion in 2025 at a CAGR of 17%.

The cellular immunotherapy market consists of revenues generated by the companies engaged in developing, manufacturing, and sales of cellular immunotherapy drugs. Cellular immunotherapy is also known as adoptive cell therapy, a form of treatment that utilizes the cells of the immune system to eliminate diseases including non-Hodgkin lymphoma, cancer, and acute lymphoblastic leukaemia.

The cellular immunotherapy market covered in this report is segmented by therapy into tumor-infiltrating lymphocyte (TIL) therapy; engineered T cell receptor (TCR) therapy; chimeric antigen receptor (CAR) T cell therapy; natural killer (NK) cell therapy. It is also segmented by primary indication into b-cell malignancies; prostate cancer; renal cell carcinoma; liver cancer; non-Hodgkin lymphoma; others and by application into prostate cancer; breast cancer; skin cancer; ovarian cancer; brain tumour; lung cancer; others.

The high cost of cellular immunotherapies is anticipated to hinder the cellular immunotherapy’s market growth.CAR-T therapy is a type of cellular immunotherapy and only two have been approved in the USA.

The price of Yescarta and Kymriah is more than $350,000 per treatment in the USA, which is highly unaffordable for a majority of the patients especially with low income. The high cost of cellular immunotherapies discourages patients to opt for this drug, thereby, impacting the demand and the market negatively.

Companies in the cellular immunotherapy market are focusing on developing off-the-shelf allogeneic therapies for new and improved cancer treatment.Off-the-shelf allogeneic therapies are produced from the cells of donors instead of the patient cells as in the case of autologous therapy.

Their non-customized nature provides advantages such as cost-effectiveness, large scale, fast, and quality control production. For instance, in November 2019, Precision Biosciences, Inc., a biotechnology company, has created a new generation allogeneic CAR-T therapy and is conducting an ongoing trial of this therapy by creating its first off-the-shelf allogeneic CAR-T therapy candidate known as PBCAR0191. This is in collaboration with Servier, an international pharmaceutical company, and is mainly for the patients in need of advanced cancer treatment options. Additionally, in August 2020, Acepodia, a US-based next-generation cell immuno-technology company, initiated a phase 1 clinical trial for evaluating ACE1702 an allogeneic, off-the-shelf NK cell therapy for the treatment of solid tumors.

In April 2020, resTORbio, Inc., a US-based biopharmaceutical company specialized in the development and commercialization of drugs used for the treatment of aging-related diseases, merged with Adicet Bio, Inc., a biopharmaceutical company, for an undisclosed amount. Both the companies continue their operations as ‘Adicet Bio’. This merger is expected to help the companies in advancing allogeneic gamma-delta CAR-T cell therapy technology. Adicet Bio, Inc. is a US-based company specialized in the development of Adicet’s off-the-shelf allogeneic gamma delta T cell therapies for oncology and other indications.

Increasing research and successful clinical trials in cellular immunotherapy are expected to drive the growth of the cellular immunotherapy market over the forecast period.Companies are focusing on developing new cellular immunotherapies for treating different diseases.

The rapid growth in the development of cellular immunotherapy in clinical and preclinical stages in 2020 as compared to that in 2019 is projected to expand the landscape of cellular immunotherapy. Subsequently, generating higher revenues for the cellular immunotherapy market.
Read the full report: https://www.reportlinker.com/p06090633/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting